After determining the significantly altered miRNAs’ differential potentials between the IP and FP phases, we evaluated their efficiency in discriminating treatment responses based on tumor regression grade (TRG1, TRG2, and TRG3) (Figure 5). The gene discussed is SAMM50; the disease is neoplasm.